Value investing is built on the search for companies whose market price lags their intrinsic worth, but a low multiple alone is rarely enough. The Decent Value screen refines that search by requiring a strong valuation score while still demanding acceptable profitability, financial health, and growth, ensuring that investors are not simply stepping into a value trap. NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a neuroscience-focused biopharmaceutical company that emerges from this screen with a fundamental rating of 7 out of 10, making it a compelling candidate for value-oriented investors who want quality behind the discount.
A Valuation That Stands Out
What makes NBIX particularly interesting from a value perspective is its valuation score of 8 out of 10, a notable achievement within the Biotechnology industry. The company trades at a price-to-earnings ratio of 20.28, which appears elevated in absolute terms but is significantly cheaper than its industry peers. NBIX is cheaper than 94.71% of companies in its industry on a P/E basis, and the price-to-forward-earnings ratio of 16.37 reinforces that picture, with 93.92% of peers valued more expensively.
The valuation case becomes even more compelling when growth is included in the equation. The PEG ratio, which adjusts the P/E for expected earnings growth, points to a relatively cheap valuation, and with earnings expected to grow by 36.66% in the coming years, the multiple becomes far more digestible. Investors who want to examine the underlying data can review the full fundamental analysis report.
Profitability and Health: Quality Beneath the Price
The Decent Value methodology does not simply hunt for low valuations; it demands that the underlying business is structurally sound. For NBIX, profitability is a clear strength, earning a score of 8 out of 10:
- Return on Equity: 19.62%, outperforming 94.51% of industry peers
- Return on Invested Capital: 13.53%, better than 95.49% of the industry
- Profit Margin: 21.55%, better than 94.12% of peers
- Gross Margin: 98.17%, among the best in the industry
Financial health is equally critical to the value thesis, as a cheap stock can quickly turn sour if the balance sheet deteriorates. NBIX scores a solid 7 out of 10 on health, supported by a debt-free balance sheet, a debt-to-equity ratio of zero, and an Altman-Z score of 8.41, which signals a low risk of bankruptcy. The current ratio of 2.93 also indicates that short-term obligations are comfortably covered.
Growth That Justifies the Valuation
A stock can appear undervalued for good reason when earnings are in decline, but that is not the case here. NBIX earns a growth rating of 9 out of 10, backed by strong historical performance:
- EPS growth over the past year: 142.31%
- Average annual EPS growth over the past years: 31.39%
- Revenue growth over the past year: 34.42%
- Average annual revenue growth: 22.29%
Forward estimates are equally encouraging, with EPS expected to grow by 32.30% per year and revenue by 14.75% annually over the next few years. That combination of past and projected growth helps bridge the gap between the current share price and the company's intrinsic value.
Why This Matters for Value Investors
For value investors, the pairing of a reasonable valuation with strong profitability, a clean balance sheet, and solid growth is precisely what distinguishes a genuine opportunity from a value trap. A low price alone is insufficient; the business must be capable of generating returns and sustaining itself while the market eventually acknowledges its worth. NBIX appears to offer that blend, with its fundamentals suggesting the current valuation does not fully reflect the company's earnings power and growth trajectory.
Risks remain, of course. The company pays no dividend, which may deter income-focused investors, and the biopharmaceutical sector carries inherent uncertainties around pipeline development and regulatory outcomes. The recent decline in profit and operating margins is also worth monitoring, as it could signal pricing pressure or rising costs ahead.
Investors who want to apply this same methodology to other stocks can use this stock screener to find more decent value opportunities.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount
Value investing is built on the search for companies whose market price lags their intrinsic worth, but a low multiple alone is rarely enough. The Decent Value screen refines that search by requiring a strong valuation score while still demanding acceptable profitability, financial health, and growth, ensuring that investors are not simply stepping into a value trap. NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a neuroscience-focused biopharmaceutical company that emerges from this screen with a fundamental rating of 7 out of 10, making it a compelling candidate for value-oriented investors who want quality behind the discount.
A Valuation That Stands Out
What makes NBIX particularly interesting from a value perspective is its valuation score of 8 out of 10, a notable achievement within the Biotechnology industry. The company trades at a price-to-earnings ratio of 20.28, which appears elevated in absolute terms but is significantly cheaper than its industry peers. NBIX is cheaper than 94.71% of companies in its industry on a P/E basis, and the price-to-forward-earnings ratio of 16.37 reinforces that picture, with 93.92% of peers valued more expensively.
The valuation case becomes even more compelling when growth is included in the equation. The PEG ratio, which adjusts the P/E for expected earnings growth, points to a relatively cheap valuation, and with earnings expected to grow by 36.66% in the coming years, the multiple becomes far more digestible. Investors who want to examine the underlying data can review the full fundamental analysis report.
Profitability and Health: Quality Beneath the Price
The Decent Value methodology does not simply hunt for low valuations; it demands that the underlying business is structurally sound. For NBIX, profitability is a clear strength, earning a score of 8 out of 10:
Financial health is equally critical to the value thesis, as a cheap stock can quickly turn sour if the balance sheet deteriorates. NBIX scores a solid 7 out of 10 on health, supported by a debt-free balance sheet, a debt-to-equity ratio of zero, and an Altman-Z score of 8.41, which signals a low risk of bankruptcy. The current ratio of 2.93 also indicates that short-term obligations are comfortably covered.
Growth That Justifies the Valuation
A stock can appear undervalued for good reason when earnings are in decline, but that is not the case here. NBIX earns a growth rating of 9 out of 10, backed by strong historical performance:
Forward estimates are equally encouraging, with EPS expected to grow by 32.30% per year and revenue by 14.75% annually over the next few years. That combination of past and projected growth helps bridge the gap between the current share price and the company's intrinsic value.
Why This Matters for Value Investors
For value investors, the pairing of a reasonable valuation with strong profitability, a clean balance sheet, and solid growth is precisely what distinguishes a genuine opportunity from a value trap. A low price alone is insufficient; the business must be capable of generating returns and sustaining itself while the market eventually acknowledges its worth. NBIX appears to offer that blend, with its fundamentals suggesting the current valuation does not fully reflect the company's earnings power and growth trajectory.
Risks remain, of course. The company pays no dividend, which may deter income-focused investors, and the biopharmaceutical sector carries inherent uncertainties around pipeline development and regulatory outcomes. The recent decline in profit and operating margins is also worth monitoring, as it could signal pricing pressure or rising costs ahead.
Investors who want to apply this same methodology to other stocks can use this stock screener to find more decent value opportunities.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »